-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) CO-FORMULATED WITH HALOZYME'S ENHANZE® TECHNOLOGY FOR THE TREATMENT OF ADVANCED HEAD AND NECK CANCER

Reuters·11/06/2026 14:57:39

Please log in to view news